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Abstract
Type VII collagen, the major component of anchoring fibrils, serves as tight adhesion of skin basement membrane zone
(BMZ) through its amino-terminal non-collagenous (NC1) domain. The NC1 domain is targeted by autoantibodies of an
acquired blistering skin disease termed epidermolysis bullosa acquisita (EBA) naturally occurring in humans and dogs. We
cloned the full-length canine type VII collagen NC1 domain cDNA and delineated its molecular and immunological
characteristics. The canine NC1 domain cDNA consists of 3759 nucleotides encoding for 1253 amino acids, with a molecular
mass of approx. 134 kDa and a 17 amino acid signal peptide. The expression of canine type VII collagen was confirmed by
Northern blot analysis and by a rabbit antibody raised against a 17 amino acid peptide deduced from canine NC1 sequence.
Comparison of canine NC1 with the corresponding human sequence indicated 86.7% and 87.6% identity at the nucleotide
and deduced amino acid levels respectively. The protein homology reached greater than 95% within two immunodominant
epitope areas. Furthermore, human EBA autoantibodies and a rabbit anti-human NC1 cross-reacted with canine skin BMZ
and the newly synthesized canine type VII collagen. The molecular and immunological identities between human and canine
NC1 domains suggest that NC1 may be critical for the EBA development. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Type VII collagen is the major component of an-
choring ¢brils in skin basement membrane zone
(BMZ), extending from the lamina densa of the epi-
dermal basement membrane to the papillary dermis
connective tissue [1,2]. cDNA cloning and amino
acid analysis reveal that human type VII collagen is
composed of three identical K-chains, each consisting
of an approx. 145 kDa central collagenous triple-he-
lical segment characterized by a repeating Gly-X-Y
amino acid sequence with several interrupted imper-
fections. The collagenous domain is £anked by a
0925-4439 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
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Abbreviations: BMZ, basement membrane zone; EBA, epider-
molysis bullosa acquisita; GSP, gene-speci¢c primer; NC, non-
collagenous; PCR, polymerase chain reaction; RACE, rapid am-
pli¢cation of cDNA end; RT, reverse transcription; UTR, un-
translated region
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large, approx. 145 kDa amino-terminal non-collage-
nous domain (NC1), and a smaller approx. 34 kDa
carboxyl-terminal non-collagenous domain (NC2)
[3,4]. In matrix, type VII collagen molecules form
anti-parallel tail-to-tail dimers with a small carbox-
yl-terminal overlap, and the most portion of NC2
domain is proteolytically removed during the assem-
bly of the mature collagen VII into the skin BMZ
[5,6]. The antiparallel dimers then aggregate laterally
in a non-staggered manner to form anchoring ¢brils
that contain large globular NC1 domains pointing
outwards [3]. Structurally, the NC1 domain consists
of distinct subdomains with homology to various
adhesive proteins. These include a domain with
40% homology to the cartilage matrix protein, do-
mains with homology to nine consecutive ¢bronectin
type III-like repeats, a domain with homology to the
von Willebrand factor A, and a domain rich in cys-
teine and proline at the carboxyl-terminal end of
NC1 [7,8]. Also, the NC1 domain contains three con-
sensus sequences, NXS/T, for N-linked glycosylation
and a potential cell attachment site RGD motif
[9,10]. The NC2 domain contains a segment with
homology to the Kunitz protein inhibitor molecule,
but its function is currently unknown [7,10,11].
The major function of type VII collagen is to con-
nect lamina densa to the dermal structure and its
NC1 domain serves as the major binding site with
other BMZ components. Studies have demonstrated
that NC1 domain binds to di¡erent types of dermal
collagens and other proteins, and may play an im-
portant role in the attachment of the NC1 domain to
other BMZ structures within the lamina densa and
sublamina densa zone [12^14]. Solid phase binding
studies suggest that it interacts with type IV collagen,
a major component of the lamina densa, and with
anchoring plaques [15]. A eukaryotic recombinant
full-length NC1 protein, found to resemble authentic
NC1 in structural and functional properties, exhibits
speci¢c interaction with the lamina lucida anchoring
¢lament components, the laminin-5/6 complex, and
with the dermal components, ¢bronectin and type I
collagen [16]. The connecting function of type VII
collagen is also supported by evidence from clinical
diseases. In inherited skin disease dystrophic epider-
molysis bullosa, in which several mutations have
been found in the type VII collagen gene, the anchor-
ing ¢brils (type VII collagen) are diminished or ab-
sent, and subepidermal blisters were observed [17].
Furthermore, when IgG autoantibodies perturb the
NC1 domain of type VII collagen in patients with an
acquired autoimmune blistering disease epidermoly-
sis bullosa acquisita (EBA), skin fragility and sub-
epidermal blisters were also observed [18^22]. Inter-
estingly, both the inherited disease dystrophic
epidermolysis bullosa and the autoimmune disease
EBA have been found to occur in dogs, and the
autoantibodies from canine EBA patients also tar-
geted the NC1 domain of type VII collagen [23,24].
The occurrence of EBA in canine patients raises the
possibility that canine may be a suitable animal spe-
cies for developing an autoimmune disease model for
EBA. Towards that end, we set out to isolate the
gene encoding for the canine NC1 domain of type
VII collagen. The impetus for this work was to ask
whether a signi¢cant homology existed between the
human and dog EBA, which could account for the
natural occurrence of the disease in both species. In
particular, we wished to determine whether there
were signi¢cant molecular and immunological simi-
larities between human and canine EBA NC1 do-
mains.
2. Materials and methods
2.1. Cell cultures
A canine squamous cell carcinoma line was ob-
tained from Dr. Rosol (Ohio State Univ., Columbus,
OH). These cells were originally derived from a ca-
nine oral squamous carcinoma cell line SCC 2/88 [25]
and maintained in Williams’ medium E (Gibco-BRL,
Grand Island, NY) supplemented with 10% fetal bo-
vine serum (Gibco-BRL), 10 ng/ml EGF (Gibco-
BRL), 0.1 nM cholera toxin (Gibco-BRL), and
2.0 mM L-glutamine (Gibco-BRL).
2.2. RNA isolation and reverse
transcription-polymerase chain reaction
(RT-PCR)
Total RNA was prepared from SCC 2/88 cells us-
ing a standardized solution RNAzol (TEL-TEST,
Friendswood, TX) according to the manufacturer’s
instruction. One half Wg of total RNA was used in
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each RT-PCR reaction using an XL RT-PCR kit
(Catalog No. N808-0205, Perkin Elmer, Foster
City, CA). The RT conditions were 60‡C for 60 min
on a GeneAmp 2400 PCR System (Perkin Elmer,
Foster City, CA), and the PCR reaction was pre-
ceded by one cycle of denaturation (94‡C, 1 min),
followed by 20 cycles of 94‡C, 15 s; 65‡C, 3 min
45 s; and by another 20 cycles of 94‡C, 15 s; and
65‡C, 3 min 45 s with 15 s anneal/extend autoexten-
sion. An additional 10 min of extension (72‡C) was
performed after 2 U of Taq polymerase (Perkin El-
mer) was added to the PCR product for the purpose
of creating the TA hanging. The primer pairs used in
the RT-PCR experiments were designed from the
human type VII collagen cDNA sequence as listed
in Table 1.
2.3. Rapid ampli¢cation of 5P-cDNA end assay
In order to get cDNA 5P-end, 5P-rapid ampli¢ca-
tion of cDNA end (RACE) was performed using a
kit (Gibco-BRL) with 0.5 Wg of total RNA from
canine squamous carcinoma cells. cDNA synthesis
was primed using a gene-speci¢c antisense primer
(GSP1): 5P-AATCCCTCCAGGAAACCTCCCAC-
TTC-3P and SuperScript II. Reaction condition was
42‡C for 30 min on a GeneAmp 2400 PCR System.
After ¢rst strand cDNA synthesis, the original
mRNA was removed by treatment with RNase (H
and T1) and the cDNA puri¢ed and a homopolymer-
ic tail was added to the 3P-end of the cDNA with
terminal deoxynucleotidyl transferase and dCTP.
The tailed cDNA was then ampli¢ed by PCR using
Abridged Anchor Primer and a nested gene-speci¢c
primer (GSP2): 5P-CAGGTCACTCTCTCCCTCT-
G-3P. The PCR conditions were 94‡C, 30 s, 55‡C,
30 s, and 72‡C, 60 s for 30 cycles plus an additional
10 min of extension (72‡C). The second PCR was
performed using the same conditions with primers:
Abridged Universal Anchor Primer and GSP2.
2.4. cDNA cloning and sequence analysis
The RT-PCR products were ligated into TA clon-
ing vector (Invitrogen, San Diego, CA), according to
the manufacturer’s manual. The positive clones were
ampli¢ed and the puri¢ed DNA was sequenced by
the standardized Sanger’s chain-termination method
using [K-35S]dATP [26]. Sequence analyses, align-
ments, and amino acid translations were performed
using AssemblyLIGN software (Oxford Molecular,
Campbell, CA).
2.5. Northern blot hybridization
Northern blot hybridization was performed as pre-
viously described [16]. The total RNA was size-frac-
tionated and transferred to nylon membranes (Gene-
Screen Plus, DuPont NEN) and hybridized with a
32P-labeled (random-primer labeling kit, BMB, Indi-
anapolis, IN) human type VII collagen cDNA.
2.6. Electrophoresis and immunoblotting
Immunoblotting was performed as previously de-
scribed [27]. At con£uence, the conditioned medium
of SCC2/88 cultures was collected and concentrated.
The medium proteins were vertically separated on a
Table 1
Sequence-speci¢c primers for RT-PCR
Clones Nucleotide sequences (5PC3P) Length of PCR product (bp)
dc1/c30 Downstream (RT) ATGACGCTGCGGCTCCTGGTGG 525
Upstream (PCR) ATTCCCACAGCAAACAGCTTGACG
c29/c18 Downstream (RT) GAAGTCCCAGGACCTGGTGGAC 1055
Upstream (PCR) TTTGGATCCTGCTGCAGCTGGTGGAA
c21/c14 Downstream (RT) CTGAGTACCGCCTCACACTCTAC 994
Upstream (PCR) CTGTAGGCTGTGGCTCCAGTGAC
c19/c12 Downstream (RT) TGCTTCCAGCGACGTTCTACGG 1099
Upstream (PCR) CCCAGGAGCATCCGGTGCTAATA
c5/c4c Downstream (RT) GCCGTGGTCACAGCTCACAGATAC 351
Upstream (PCR) TCCCCCTTCTGGCCCTTTGGACA
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mini slab gel SDS-PAGE system under reducing con-
ditions (Novex, San Diego, CA). The proteins were
then horizontally transferred to nitrocellulose mem-
branes (Bio-Rad, Hercules, CA), and the membranes
then incubated with a rabbit polyclonal antibody
raised against full-length human NC1 domain of
type VII collagen [16,28]. The immunoreactions
were completed with peroxidase-conjugated goat
anti-rabbit IgG (1:10 000, Kirkkegaard and Perry,
Gaithersburg, MD) and visualized with a chemilumi-
nescence substrate on autoradiographic ¢lms (Bio-
Rad).
2.7. Polyclonal anti-peptide antibody production
A peptide of 17 amino acids in size was generated
from the amino acid sequence deduced from the ca-
nine type VII collagen cDNA near the carboxyl ter-
minus of NC1: H2N-DESLRGDIFNPIREAQA and
coupled with keyhole limpet hemocyanin at the N
terminus (Research Genetics, Huntsville, AL). The
synthetic peptide was puri¢ed to s 90% purity by
HPLC and then injected into two rabbits for poly-
clonal antibody production (Research Genetics).
Post-immune serum containing high titer (1:80 000)
antibodies against the peptide as determined by ELI-
SA was used in the indirect immuno£uorescence
studies described below.
2.8. Indirect immuno£uorescence staining
Indirect immuno£uorescence staining was per-
formed as previously described [27]. Six Wm thick
cryosections of intact or chemically separated canine
skin by 1 M salt [29] were used as substrates. Chemi-
cally separated skin, which split at middle lamina
lucida, has been used by immunopathologists to dis-
tinguish circulating autoantibodies that bind to type
VII collagen (dermal £oor binding pattern) from
those that bind to type XVII collagen (epidermal
roof binding pattern) [29]. In the studies with human
patients’ sera, the incubation of diluted sera was fol-
lowed by incubation with £uorescein-conjugated goat
anti-human IgG (Cappel, Durham, NC). In the stud-
ies with rabbit antisera, the incubation of diluted sera
was followed by incubation with £uorescein-conju-
gated monoclonal mouse anti-rabbit IgG (Q-chain
speci¢c, Sigma, St. Louis, MO). Pre-immune rabbit
serum at the same dilutions was used as negative
control. The specimens were examined under an
Olympus BX60 £uorescence microscope equipped
with epi-illumination and photographed.
2.9. Immunoelectron microscopy
Indirect immunoelectron microscopy was per-
formed with a rabbit polyclonal antibody against
human NC1 domain of type VII collagen [16] on
canine skin using a standardized peroxidase-antiper-
oxidase method with some modi¢cations [28,30,31].
The ultrathin sections (80 nm) were examined under
a Hitachi HU-12A transmission electron microscope
and photographed.
3. Results and discussion
3.1. Isolation and sequence analysis of canine type VII
collagen
According to human type VII collagen cDNA se-
quences, ¢ve pairs of primers were used to amplify
overlapped cDNA fragments, which covered the full-
length NC1 domain of canine type VII collagen
cDNA, and a 5P-RACE was performed to obtain
the 5P-untranslated region (UTR). The total number
of nucleotides isolated was 3792 bp, which included
33 bp in 5P-UTR and 3759 bp of entire NC1 domain
encoding a polypeptide of 1253 amino acids (Fig. 1).
This canine coding region has the precisely same
number of cDNA and protein sequences as previ-
ously reported for the human type VII collagen
NC1 [8]. There is, however, one amino acid less
than that of the mouse NC1 domain at position
+14 from the start codon methionine [10] (Fig. 2).
Computer-assisted sequence analyses revealed 87%
Table 2
Percent identity of type VII collagen NC1 immunodominant
epitopes in human/dog and human/mouse
Epitopes (amino acids) (%)
E1 E2 E3 E4 Ea Eb
Human/dog 90.2 91.5 82.4 79.2 100 95
Human/mouse 82.1 89.1 78.8 73.3 91.4 84.4
E1^4, see [21]. Ea and b, see [22].
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Fig. 1. Nucleotide sequences of the entire canine type VII collagen NC1 domain cDNA and predicted amino acids. The sequence con-
tains a total of 3792 bp which include the 5P-UTR (1^33 bp) and the NC1 coding region (34^3792 bp) encoding 1253 amino acids.
The nucleotide sequence has been deposited with the GenBank nucleotide sequence database (accession No. AF 042093).
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and 88% identity at nucleotide and amino acid levels
respectively between the isolated canine coding se-
quence and the human counterpart. The homology
is higher than that between human and mouse, which
accounted for 83% identity at both nucleotides and
deduced amino acid levels. However, the homology
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between human and dog at amino acid level reaches
90^100% at several major antigenic regions within
NC1 domain (Table 2, Fig. 2). This means there is
a greater similarity within the NC1 domain between
human and canine sequences than that between hu-
man and murine sequences. However, the 5P-UTR of
the human and canine NC1 genes between nucleoti-
des 333 and 34 are completely di¡erent.
3.2. Characterization of deduced primary sequence of
the canine type VII collagen NC1 domain
The deduced amino acid sequence of the canine
type VII collagen NC1 domain protein consists of
1253 residues with a calculated molecular mass of
approx. 134 kDa. This includes a 16 amino acid pu-
tative signal sequence. Compared with the human
and the mouse sequences, the most likely cleavage
site for canine signal peptidase was found to be the
peptide bond between amino acids alanine and gly-
cine at positions +16 and +17, which were similar to
that of the human. However, this glycine was re-
placed by the glutamic acid at position +17 in its
human counterpart [7,10]. The predicted 16 amino
acid signal peptide is relatively hydrophobic, and
the cleavage site conforms to the 33, 31 rule [32].
Examination of the canine primary sequence within
the NC1 domain allowed identi¢cation of a subdo-
main with homology to various adhesive proteins,
similar to those in human and mouse [7,10]. These
include a segment with 40% homology to the carti-
lage matrix protein; nine consecutive segments with
homology to ¢bronectin type III-like repeats; and a
segment with homology to the von Willebrand factor
A. Furthermore, the canine type VII collagen also
contains eight conserved cystine residues within the
NC1 domain and a conserved RGD amino acid trip-
let which has been suggested to serve as a site for
integrin-mediated cell attachment [33]. Canine NC1
also has three NXT/S sequences for N-glycosylation
[9]. Thus there is considerable conservation between
the human, mouse and canine sequences and the pre-
dicted domain organization of the protein, suggesting
functional importance to these protein segments.
By Northern blot hybridization, canine squamous
cell carcinoma total RNA demonstrated that the ca-
nine type VII collagen has a similar size mRNA to
that of human type VII collagen. As shown in Fig. 3,
canine type VII collagen mRNA co-migrates with a
band of human RNA (extracted from human cul-
tured keratinocytes) hybridized by the same cDNA
probe. Both of the bands are approx. 9 kb in length.
Thus, human and canine type VII collagen mRNAs
are identical in size. By immunoblotting with a rabbit
Fig. 3. Northern blot analyses of canine and human type VII
collagen mRNA. Hybridization of canine squamous cell carci-
noma total RNA (lane C) with a human type VII collagen
cDNA probe identi¢es a 9 kb mRNA (arrow), co-migrating
with a 9 kb human keratinocyte mRNA probed with the same
probe (lane H).
Fig. 2. Direct comparison of the human (upper line), canine
(middle line), and mouse (lower line) deduced amino acid se-
quences of the entire NC1 domain. The alignment of the se-
quence was performed with the AssemblyLIGN program. The
single dots indicate identities of the canine and murine corre-
sponding sequences as compared to human sequence. The pre-
dicted signal peptide is underlined. The conserved cystine resi-
dues are indicated by open squares above the sequences.
Potential N-glycosylation sites (NXS/T) are marked by under-
lined brackets. The presence of conserved RGD is marked by
0. Immunodominant epitopes Ea and Eb (see [22]) are indicated
by inclusive arrowheads. The borders between the peptide seg-
ments with homology to cartilage matrix protein (CMP), nine
consecutive ¢bronectin type III-like repeats (FN1^9), von Wille-
brand factor A domain (VWF-A), as well as the region rich in
cysteine and proline residues (C/P) are indicated by T-shaped
brackets above the sequences.
6
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anti-human NC1 polyclonal antibody, we also dem-
onstrated an approx. 290 kDa canine native type VII
collagen in cultured canine squamous carcinoma cell
conditioned medium, which co-migrated with the
290 kDa type VII collagen in human WISH cell con-
ditioned medium (Fig. 4). These data indicate that
the gene product of canine type VII collagen is iden-
tical in size to that of human type VII collagen. Fur-
thermore, these data demonstrate that signi¢cant im-
munological homology exists between human and
canine NC1 domains.
In order to con¢rm that the isolated cDNA se-
quence indeed encodes a BMZ component, we per-
formed immuno£uorescence assay on canine skin us-
ing a rabbit polyclonal antibody raised against a 17
amino acid peptide deduced from canine type VII
collagen cDNA sequence. We showed that this rabbit
antibody labeled the BMZ of normal canine intact
skin substrates, whereas pre-immune serum of the
same dilution from the same rabbit did not label
the BMZ (Fig. 5). This con¢rms that the nucleotide
sequence of canine type VII collagen cDNA is a true
sequence encoding a skin BMZ component. Further-
more, a rabbit polyclonal anti-human NC1 domain
bound exclusively to the lamina densa and sublamina
densa of canine skin, with no IgG bound in the
upper lamina lucida as documented by indirect im-
munoelectron microscopy (Fig. 6). The same result
was obtained with human skin (data not shown).
3.3. Canine type VII collagen is antigen of EBA
autoantibodies
EBA is an acquired autoimmune blistering skin
disease characterized by the presence of circulating
Fig. 5. Indirect immuno£uorescence microscopic studies of in
vivo expression of canine type VII collagen in the basement
membrane. Intact dog skins were incubated with a rabbit poly-
clonal antibody raised against a 17 amino acid synthetic peptide
deduced from the canine type VII collagen cDNA sequence,
followed by £uorescein-conjugated mouse anti-rabbit IgG anti-
bodies. The anti-peptide antibody (b), but not the pre-immune
serum (a), labeled the canine skin BMZ (arrowheads). Bars =
10 Wm.
Fig. 6. Indirect immunoelectron microscopic localization of type
VII collagen in the canine basement membrane. The results
showed that binding sites (black) of IgG antibodies from a rab-
bit anti-human NC1 antibody localized exclusively to the lami-
na densa (gray) and sublamina densa of canine skin. No IgG
was localized in the upper lamina lucida. E, epidermis; D, der-
mis; Bar = 0.3 Wm.
Fig. 4. Immunoblot analyses of canine and human type VII col-
lagens. Conditioned medium proteins obtained from canine
squamous cell carcinoma cultures (lane C) and human WISH
cell culture (lane H) were separated by 6% SDS-PAGE and
transferred to nitrocellulose membrane and then labeled by a
rabbit polyclonal antibody raised against full-length human NC1
domain of type VII collagen. The arrow indicates a 290 kDa type
VII collagen protein. M, molecular weight standards.
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and tissue-bound IgG autoantibodies to the skin
BMZ. Human EBA autoantibodies recognized the
NC1 domain of type VII collagen [21]. Previously,
we reported that canine EBA patient’s IgG autoanti-
bodies recognized human recombinant NC1 domain
[24]. Further indirect immuno£uorescence studies
demonstrated that human EBA patient’s serum
(with autoantibodies recognizing the type VII colla-
gen) also labeled the dermal side of canine salt-split
skin substrate (Fig. 7a), whereas a human BP pa-
tient’s serum (with autoantibodies recognizing the
type XVII collagen) labeled the epidermal side of
the same substrate (Fig. 7b). This means human
EBA autoantibodies cross-react with canine skin
BMZ. We therefore con¢rm, immunologically, that
the NC1 domains of human and dog share signi¢-
cant homology. On the basis of similarity of type VII
collagen between human and dog in primary struc-
ture and immunological reactivity, we conclude that
our results support that (1) the autoantibody against
NC1 domain is a common feature in both human
and canine EBA and may be a critical factor in the
development of human and canine EBA blisters; (2)
human and canine EBA probably share a similar or
identical pathogenic mechanism; and (3) the dog
may be a species in which an active inducible animal
model for EBA can be created. The current lack of a
murine model of EBA may be due to the lack of
critical initiating factors in the murine system. The
cloning of the cDNA encoding for this disease-tar-
geted protein in canine may allow the development
of an active canine EBA model. While the inbred
murine system provides an advantage of allowing
de¢ned immunogenetic analyses, the outbreed canine
system provides a unique advantage in the under-
standing of human disease. The study of disease in
canine system is clinically relevant, since it is a true
re£ection of the outbreed nature of the human pa-
tient population.
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